In vivo studies in two xenograft tumor models have also shown that melanoma antigen-specific CXCR2-engineered T cells improved tumor migration and antitumor activity in mice bearing MC38/gp100 tumors or CXCL1-expressing tumors (82). This evidence concerns the gene CXCR2 and melanoma.